The Company had $448.7M in cash, cash equivalents, and investments as of December 31 …”We are more enthusiastic than ever about the potential for allogeneic CAR T to transform the field,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. “From our innovative ALPHA3 trial which is designed to embed cema-cel as part of a curative first-line regimen for patients with large B cell lymphoma, to specifically creating a CAR T that can meet the unique needs of patients with autoimmune disease and reduce reliance on lymphodepletion, our development approach focuses on the distinctive attributes of an off-the-shelf alternative and creates an advantage for our AlloCAR T programs.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALLO:
- Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
- Allogene, Arbor enter global gene editing license agreement
- Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
- Allogene Therapeutics management to meet with Truist
- Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
